Catalent announces agreement to provide scale-up expertise and manufacturing capabilities TFF Pharmaceuticals, a developer of dry powder formulations for a range of biotherapeutics; agreement gives access to the TFF technology

Sample article from our Health Care Sector

AUSTIN, Texas & SOMERSET, New Jersey , March 2, 2022 (press release) –

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) and Catalent today announced their collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics through the application of TFF Pharmaceuticals’ patented Thin Film Freezing (TFF) technology. Under the agreement, Catalent will provide its scale-up expertise and manufacturing capabilities to TFF Pharmaceuticals as its preferred development and manufacturing partner, and Catalent will be able to offer its customers access to the innovative TFF technology, which has the potential to increase the adoption of the pulmonary route for the systemic delivery of biotherapeutics.

“Catalent is widely known as a global leader in enabling pharmaceutical development and manufacturing and has distinguished itself by demonstrating cutting-edge expertise across multiple modalities and innovative projects. We are therefore delighted to significantly expand our collaboration with the Catalent team,” stated Glenn Mattes, Chief Executive Officer of TFF Pharmaceuticals. “This strategic collaboration significantly expands our access to manufacturing capabilities and provides scalability for our technology, while simultaneously affording us the opportunity to build our portfolio of technology licensing partnerships.”

Jonathan Arnold, President, Oral and Specialty Delivery at Catalent added, “Catalent is pleased to leverage its extensive expertise in the development and CGMP manufacture of dry powders in order to potentially bring TFF Pharmaceuticals’ unique and differentiated technology to scale.”

Thin Film Freezing may potentially be used to generate dry powder formulations for inhalation, and it complements Catalent’s existing capabilities in spray drying for the development of inhalable drugs established by its 2021 acquisition of the manufacturing and packaging operations of Acorda Therapeutics in Boston, Massachusetts.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.